FLAG Therapeutics
Near-term clinical-stage biotechnology company focused on discovery and development of water-soluble, multi-acting small-molecule therapeutics for difficult-to-treat cancers, with a lead small-molecule candidate projected to enter Phase 1/2 pediatric clinical development in early 2026. The organization operates three discovery platforms (anti-angiogenic/tubulin inhibitors; folate receptor–targeted GARFTase inhibitors; folate receptor–targeted SHMT2 inhibitors), maintains an extensive patent estate, and holds regulatory designations for selected oncology indications.
Industries
Nr. of Employees
small (1-50)
FLAG Therapeutics
Raleigh, North Carolina, United States, North America
Products
Lead small-molecule candidate (anti-angiogenic/tubulin inhibitor) for gliomas
Investigational water-soluble small-molecule therapeutic designed to combine anti-angiogenic receptor inhibition with tubulin inhibition; optimized for BBB penetration and reduced P-gp efflux; advanced toward Phase 1/2 pediatric development.
Folate receptor–targeted antifolate candidates (GARFTase inhibitors)
Investigational small molecules designed for selective uptake by tumors overexpressing folate receptor-α and inhibition of GARFTase to disrupt purine synthesis and cell replication.
Folate receptor–targeted SHMT2 inhibitor candidates
Investigational small molecules targeting folate receptor–α and mitochondrial/cytosolic one‑carbon metabolism via SHMT2 inhibition for indications such as pancreatic cancer.
Folate Receptor-⍺
Multi-acting single agent for tumors that over express FR-α, including Ovarian Cancer and Mesothelioma.
Folate Receptor-⍺ / SHMT-2 Inhibitor
Multi-acting single agent for tumors that over express FR-α, including Pancreatic Cancer.
FLAG-094
An investigational multi-acting, water-soluble small molecule therapeutic designed to target, bind and kill cancer cells through multiple mechanisms of action, specifically for Epithelial Ovarian Cancer (EOC) and mesothelioma.
Lead small-molecule candidate (anti-angiogenic/tubulin inhibitor) for gliomas
Investigational water-soluble small-molecule therapeutic designed to combine anti-angiogenic receptor inhibition with tubulin inhibition; optimized for BBB penetration and reduced P-gp efflux; advanced toward Phase 1/2 pediatric development.
Folate receptor–targeted antifolate candidates (GARFTase inhibitors)
Investigational small molecules designed for selective uptake by tumors overexpressing folate receptor-α and inhibition of GARFTase to disrupt purine synthesis and cell replication.
Folate receptor–targeted SHMT2 inhibitor candidates
Investigational small molecules targeting folate receptor–α and mitochondrial/cytosolic one‑carbon metabolism via SHMT2 inhibition for indications such as pancreatic cancer.
Folate Receptor-⍺
Multi-acting single agent for tumors that over express FR-α, including Ovarian Cancer and Mesothelioma.
Folate Receptor-⍺ / SHMT-2 Inhibitor
Multi-acting single agent for tumors that over express FR-α, including Pancreatic Cancer.
FLAG-094
An investigational multi-acting, water-soluble small molecule therapeutic designed to target, bind and kill cancer cells through multiple mechanisms of action, specifically for Epithelial Ovarian Cancer (EOC) and mesothelioma.
Expertise Areas
- Small-molecule oncology drug discovery
- Medicinal chemistry and computational drug design
- Preclinical in vitro and in vivo efficacy testing
- Blood–brain barrier–penetrant drug design
Key Technologies
- Small-molecule therapeutics
- Anti-angiogenic and tubulin-inhibition mechanisms
- Folate receptor–targeted antifolates (GARFTase inhibitors)
- SHMT2 enzyme inhibition
News & Updates
Poster presentation on formulation of tablet dosage form to support Phase 1/2 pediatric clinical testing.
Poster reporting in vitro activity of the lead candidate against diffuse intrinsic pontine glioma presented at ISPNO 2024.
Announcement of over $500,000 in equity and impact funding from venture and mission-driven investors.
Abstract/poster describing preclinical in vitro activity against DIPG and related data.
Selected publications covering microtubule targeting agents, antifolate mechanisms, and one‑carbon metabolism inhibitors.
Regulatory orphan drug designation granted for a glioma indication.
Poster presentation on formulation of tablet dosage form to support Phase 1/2 pediatric clinical testing.
Poster reporting in vitro activity of the lead candidate against diffuse intrinsic pontine glioma presented at ISPNO 2024.
Announcement of over $500,000 in equity and impact funding from venture and mission-driven investors.
Abstract/poster describing preclinical in vitro activity against DIPG and related data.
Selected publications covering microtubule targeting agents, antifolate mechanisms, and one‑carbon metabolism inhibitors.
Regulatory orphan drug designation granted for a glioma indication.